Advertisement

Does acromegaly enhance mortality?

  • John AyukEmail author
  • Michael C. Sheppard
Article

Abstract

The increased mortality associated with acromegaly was first demonstrated in early epidemiological studies. Since the seminal paper by Wright et al. in 1970, nearly 20 studies have analyzed mortality rates in over 5,000 patients with acromegaly. Overall standardized mortality rates are approximately two times higher than in the general population, relating to an average reduction in life expectancy of around 10 years. The excess deaths are due predominantly to cardiovascular, cerebrovascular and respiratory disease. Malignancy deaths have been high in some studies but not others; in the largest series looking at cancer mortality in acromegaly, overall cancer deaths were not increased, but colon cancer mortality was higher than expected. In 1993, Bates et al. first demonstrated that outcome was related to the latest measurable growth hormone (GH), and treatment to reduce GH levels led to improved outcomes. Other factors predicting poor outcome include the presence of hypertension and diabetes. On the basis of current evidence, a latest GH of less than 2–2.5 μg/L is a better predictor of good outcome than a normal insulin-like growth factor-1 (IGF-1), possibly due to discrepancy between GH and IGF-1 at low GH levels. There is some evidence to suggest a more stringent GH cut-off (less than 1 μg/L) may yield additional benefit but further studies are required to investigate any added risk of increased mortality from hypopituitarism. Radiotherapy has been linked specifically to cerebrovascular mortality and its use in patients with acromegaly must involve a careful risk–benefit analysis in each case.

Keywords

Pituitary Growth hormone Acromegaly Radiotherapy Mortality Hypopituitarism 

References

  1. 1.
    Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970;39:1–16.PubMedGoogle Scholar
  2. 2.
    Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980;12:71–9.Google Scholar
  3. 3.
    Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987;26:481–512.Google Scholar
  4. 4.
    Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293–9.PubMedGoogle Scholar
  5. 5.
    Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95–102.Google Scholar
  6. 6.
    Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58:86–91.CrossRefGoogle Scholar
  8. 8.
    Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:1613–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151:439–46.PubMedCrossRefGoogle Scholar
  11. 11.
    Evans HM, Briggs AH, Dixon JS. In: Harris GW, Donovan BT, editors. The pituitary gland. London: Butterworth; 1966. p. 439.Google Scholar
  12. 12.
    Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest 1993;16:181–7.PubMedGoogle Scholar
  14. 14.
    Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–26.PubMedCrossRefGoogle Scholar
  16. 16.
    Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789–96.PubMedCrossRefGoogle Scholar
  17. 17.
    Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005;90:4081–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Bates AS, Van’t Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75–81.CrossRefGoogle Scholar
  24. 24.
    Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Erfurth EM, Bulow B, Eskilsson J, Hagmar L. High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results. Growth Horm IGF Res 1999;9(Suppl A):21–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998;83:2646–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxf) 1995;42:417–23.Google Scholar
  28. 28.
    Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001;86:1645–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Wabitsch M, Hauner H, Heinze E, Teller WM. The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Metabolism 1995;44:45–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53–74.PubMedCrossRefGoogle Scholar
  31. 31.
    Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18:801–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808–16.PubMedCrossRefGoogle Scholar
  33. 33.
    Peacey SR, Toogood AA, Shalet SM. Hypothalamic dysfunction in “cured” acromegaly is treatment modality dependent. J Clin Endocrinol Metab 1998;83:1682–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Barkan AL. Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf) 2003;58:132–5.CrossRefGoogle Scholar
  35. 35.
    Brada M, Rajan B, Traish D, Ashley S, Holmes-Sellors PJ, Nussey S, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38:571–8.Google Scholar
  36. 36.
    Flickinger JC, Nelson PB, Taylor FH, Robinson A. Incidence of cerebral infarction after radiotherapy for pituitary adenoma. Cancer 1989;63:2404–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 2002;57:713–7.CrossRefGoogle Scholar
  38. 38.
    O’Connor MM, Mayberg MR. Effects of radiation on cerebral vasculature: a review. Neurosurgery 2000;46:138–49.PubMedCrossRefGoogle Scholar
  39. 39.
    Wass JA. Radiotherapy in acromegaly: a protagonists viewpoint. Clin Endocrinol (Oxf) 2003;58:128–31.CrossRefGoogle Scholar
  40. 40.
    Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer. Cancer 1991;68:1673–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Melmed S. Acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001;86:2929–34.PubMedCrossRefGoogle Scholar
  42. 42.
    Jenkins PJ, Fairclough PD. Colorectal neoplasia in acromegaly. Clin Endocrinol (Oxf) 2001;55:727–9.CrossRefGoogle Scholar
  43. 43.
    Renehan AG, Odwyer ST, Shalet SM. Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf) 2001;55:731–3.CrossRefGoogle Scholar
  44. 44.
    Perry I, Stewart PM, Kane K. Colorectal screening guidelines in acromegaly. Gut 2003;52:1387.PubMedCrossRefGoogle Scholar
  45. 45.
    Renehan AG, O’Connell J, O’Halloran D, Shanahan F, Potten CS, O’Dwyer ST, et al. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 2003;35:712–25.PubMedCrossRefGoogle Scholar
  46. 46.
    Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85:193–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001;4:239–49.PubMedCrossRefGoogle Scholar
  48. 48.
    Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003;26:1242–7.PubMedGoogle Scholar
  49. 49.
    Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW. Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003;13:185–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of Medical Sciences, Queen Elizabeth HospitalUniversity of BirminghamBirminghamUK

Personalised recommendations